培美替尼的用法，培美替尼的使用说明书

Pemetinib has been approved for the treatment of cholangiocarcinoma. The drug is an inhibitor of the fibroblast growth factor receptor (FGFR). After treatment, the median progression-free survival of patients reached 6.9 months and the median overall survival reached 21.1 months. Today let’s learn more about the usage of pemetinib and the instructions for use of pemetinib.

All names for pemetinib: pemetinib, pemigatinib, pemetinib, pemazyre.

Indications for Pemetinib: This drug is used to treat cholangiocarcinoma that has metastasized (spread to other parts of the body) or is locally advanced and cannot be treated with surgery. It is also used to treat adults with diseases involving FGFR2 gene fusions or other changes in the structure of the FGFR2 gene.

Pemetinib usage and dosage:

The recommended dose of pemetinib is 13.5 mg orally daily for 14 days, followed by 7 days off in a 21-day cycle. Pemetinib can be taken with food or as a single drug without food. The treatment time can be continued until the patient's disease progresses or the patient's body develops unacceptable toxicity.

Pemetinib adverse reactions:

Vomiting, loss of appetite, weight loss, constipation, diarrhea, nausea, change in taste, stomach pain, mouth sores, dry mouth and/or dry skin; decreased urine output; or rapid heartbeat. Hair loss, fatigue, nail inflammation, headache, joint pain, painful urination, swelling and pain in limbs or joints. Blurred vision, seeing flashes of light or other vision changes, floaters in the eye, muscle spasms, numbness, or dry mouth.

Precautions for Pemetinib:

Pemetinib can cause harm to the fetus, and patients need to be aware of this potential risk before use; determine whether the patient needs to terminate pemetinib treatment based on the severity and duration of hyperphosphatemia. Pemetinib can cause retinal pigment epithelial detachment. During treatment, patients need to undergo eye examinations as directed by their doctor.

The above is the content of the instructions for use of pemetinib. Patients should take the medicine according to the doctor's instructions and should not change the dosage and method of the medicine at will. If the patient develops intolerance, he should communicate with the doctor in time and adopt a new treatment plan.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: